Back to today’s briefing

Story perspectives

Analysts Upgrade Myriad Genetics and Viavi Solutions Amid Market Fluctuations

1/10/2025

48 6

Summary

Myriad Gains Upgrade

Myriad Genetics has been given a boost with a "buy" rating from StockNews.com, despite Morgan Stanley slashing its price target from $32 to $21. Meanwhile, Viavi Solutions also shines with a "buy" upgrade, as analysts set price targets between $9.50 and $13.00. Both firms are maneuvering through a landscape of mixed market sentiments.

Summary

Experts Recommend Alternatives

Analysts are giving "Moderate Buy" ratings to companies like Charles Schwab and Fortive, but some top experts are pointing investors toward alternative stocks that could yield better returns. This shift highlights the diverse opinions and strategies in today's fluctuating market landscape, urging investors to stay informed and consider all options.

1 of 2

Myriad Gains Upgrade

Myriad Genetics has been given a boost with a "buy" rating from StockNews.com, despite Morgan Stanley slashing its price target from $32 to $21. Meanwhile, Viavi Solutions also shines with a "buy" upgrade, as analysts set price targets between $9.50 and $13.00. Both firms are maneuvering through a landscape of mixed market sentiments.

1 / 2